跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Vital Therapies, Inc.

首页临床试验发起方与机构Vital Therapies, Inc.

Vital Therapies, Inc.

ACTIVE

加利福尼亚州圣迭戈县, California, 美国www.vitaltherapies.comPublic51–100 名员工成立于: 2003-01-01

隶属于 Immunic

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

17

7 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

2003

概览

试验阶段分布

阶段

试验数

占比

1 期

5

29.4%

2 期

5

29.4%

3 期

3

17.6%

试验状态分布

进行中（未招募）

7

41.2%

已完成

4

23.5%

No Longer Available

1

5.9%

终止

3

17.6%

撤回

2

11.8%

相关临床试验

该机构主办的试验（17）

Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

Jan 2016151 名受试者

This study examines the safety and efficacy of using ELAD treatment as continuous liver support in subjects with liver failure secondary to acute hepatocellular insult with a temporal and causal relationship to alcohol, allowing time for the subject's native liver to recover and be restored to a functional state. The primary objective of the study is to evaluate the safety and efficacy of ELAD with respect to overall survival (OS) of subjects through at least Study Day 91.

进行中（未招募）

Dec 2015150 名受试者

This study examines the safety and efficacy of using ELAD treatment as continuous liver support in subjects with liver failure secondary to acute hepatocellular insult with a temporal and causal relationship to alcohol, allowing time for the subject's native liver to recover and be restored to a functional state. The primary objective of the study is to evaluate the safety and efficacy of ELAD with respect to overall survival (OS) of subjects through at least Study Day 91.

进行中（未招募）

Dec 2015150 名受试者

This study examines the safety and efficacy of using ELAD treatment as a continuous liver support to a subject with liver failure secondary to acute hepatocellular insult and alcohol use, allowing time for the subject's native liver to recover and restore to a functional state. The study's primary objective is to evaluate ELAD safety and efficacy on overall survival through at least Study Day 91, with follow-up Protocol VTL-308E providing additional survival data up to a maximum of 5 years.

进行中（未招募）

Nov 2015150 名受试者

Study examines the safety and efficacy of ELAD treatment as a continuous liver support to a subject with compromised liver function owing to severe acute alcoholic hepatitis who is a Lille score failure (Lille score >0.45), allowing time for the subject's native liver to regenerate to a functional state. The primary objective is to evaluate safety and efficacy with respect to overall survival of subjects through study termination (after last surviving enrolled subject completes Study Day 91).

进行中（未招募）

May 2015150 名受试者

Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)

Oct 20148 名受试者

To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

Apr 201418 名受试者

This study examines the safety and efficacy of using ELAD therapy as a continuous liver support in subjects with compromised liver function owing to severe acute alcoholic hepatitis (sAAH), allowing time for the subject's native liver to regenerate to a healthy state. The primary objective of the study is to evaluate safety and efficacy of ELAD with respect to overall survival (OS) of subjects through VTI-210 study termination (after the last surviving enrolled subject completes study day 91)

进行中（未招募）

Jul 2013150 名受试者

第 1 页，共 3 页

药物批准

暂无批准数据

资讯

暂无资讯文章

本页目录

概览
相关临床试验17
药物批准
资讯

返回机构列表